


Biosimilars in Oncology: Potential Value for Practices, Hospitals, and Healthcare Systems



US Costs in Oncology

- Total spending on US cancer care is **projected to rise 34%** from 2015–2030¹
- **Financial management remains the #1 concern** of surveyed hospital CEOs²
- Biosimilars **may help reduce costs in oncology**, as they have been associated with \$37 billion in savings **across all therapeutic areas where they have been introduced (e.g., inflammation, supportive care, and oncology)** since the passage of the Biosimilars Act in 2010, and are projected to produce an estimated \$104 billion in savings from 2020–2024^{3,4}

17✓



Impact of Oncology Biosimilars

- There are currently **17 approved biosimilars** covering 3 oncology therapeutic antibodies and 3 supportive care agents as of January 2021^{5,6}
- **Biosimilar alternatives are available** for 4 of the top 5 most costly oncology and supportive care **medical benefit** drugs for commercially covered patients and 4 of the top 6 most costly **oncology and supportive care medical benefit** drugs for patients on Medicare⁷
- Increased biosimilar competition has led to **decreased price for every therapeutic agent** in oncology and supportive care where biosimilars are available^{8,9}
 - Oncology therapeutic antibodies: 25%–31% reduction in ASP across therapeutic agents since biosimilar introduction^{8*}
 - Supportive care: 31%–46% reduction in ASP across therapeutic agents since biosimilar introduction^{8*}
- Oncology biosimilars have had **greater and more rapid uptake** than other biosimilars³
 - Oncology therapeutic antibodies are tracking towards nearly 60% market uptake in the first 2 years of availability³

*2Q2021
ASP, average sales price.




Pfizer Heritage in Oncology

- Pfizer has the **largest oncology biosimilar portfolio on the market** to give more patients more treatment options and is committed to supporting these options for the US healthcare system¹⁰
- Pfizer has a **robust heritage in oncology spanning over 30 years** of global experience with 23 approved oncology medicines⁸
- Pfizer is quality focused, with all biosimilars produced to meet the **same high-quality standards as its biologics**⁸

Pfizer Provides Support to Help With Seamless Biosimilar Integration

Resources are available to help practices, hospitals, and health systems integrate biosimilars through effective operational enablement, IT, monitoring, education, and communication



EHR, electronic health record;
P&T, Pharmacy and Therapeutics.

For more information, please speak with your Pfizer representative and visit [PfizerBiosimilars.com](https://www.pfizer.com/biosimilars)

References: 1. Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical care costs associated with cancer survivorship in the United States. *Cancer Epidemiol Biomarkers Prev.* 2020;29(7):1304-1312. 2. American College of Healthcare Executives. Survey: healthcare finance, personnel shortages, behavioral health, addiction issues cited by CEOs as top issues confronting hospitals in 2019. <https://www.ache.org/about-ache/news-and-awards/news-releases/top-issues-confronting-hospitals-in-2019>. Accessed February 19, 2021. 3. IQVIA. Biosimilars in the United States 2020-2024. <https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024>. Accessed February 19, 2021. 4. U.S. FDA. Biosimilars. <https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars>. Accessed February 19, 2021. 5. McGowan S, Jesse M; AmersourceBergen. Biosimilars pipeline report. https://www.amersourcebergen.com/-/media/assets/amersourcebergen/biosimilars-page/biosimilars-pipeline-report_061120. Accessed February 19, 2021. 6. US Food and Drug Administration. Biosimilar product information. <https://www.fda.gov/drugs/biosimilars/biosimilar-product-information>. Accessed February 19, 2021. 7. Magellan Rx Management. Medical Pharmacy Trend Report™. 2019. 10th edition. <https://www1.magellanrx.com/read-watch-listen/read/our-publications/medical-pharmacy-trend-report/>. Accessed February 19, 2021. 8. Data on file. Pfizer Inc., New York, NY. 9. Greene L, Singh RM, Carden MJ, Pardo CO, Lichtenstein GR. Strategies for overcoming barriers to adopting biosimilars and achieving goals of the Biologics Price Competition and Innovation Act: a survey of managed care and specialty pharmacy professionals. *J Manag Care Spec Pharm.* 2019;25(8):904-912. 10. Drugs.com. How many biosimilars have been approved in the United States? <https://www.drugs.com/medical-answers/manybiosimilars-approved-united-states-3463281/>. Updated January 14, 2021. Accessed February 19, 2021.